Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs.
Parkinson’s disease
administration routes
delivery systems
drug
nanoparticles
nanotheranostics
treatment
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
08 Apr 2021
08 Apr 2021
Historique:
received:
11
03
2021
revised:
01
04
2021
accepted:
05
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Parkinson's disease (PD) affects around ten million people worldwide and is considered the second most prevalent neurodegenerative disease after Alzheimer's disease. In addition, there is a higher risk incidence in the elderly population. The main PD hallmarks include the loss of dopaminergic neurons and the development of Lewy bodies. Unfortunately, motor symptoms only start to appear when around 50-70% of dopaminergic neurons have already been lost. This particularly poses a huge challenge for early diagnosis and therapeutic effectiveness. Actually, pharmaceutical therapy is able to relief motor symptoms, but as the disease progresses motor complications and severe side-effects start to appear. In this review, we explore the research conducted so far in order to repurpose drugs for PD with the use of nanodelivery systems, alternative administration routes, and nanotheranostics. Overall, studies have demonstrated great potential for these nanosystems to target the brain, improve drug pharmacokinetic profile, and decrease side-effects.
Identifiants
pubmed: 33917696
pii: pharmaceutics13040508
doi: 10.3390/pharmaceutics13040508
pmc: PMC8068059
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nat Rev Neurosci. 2020 Feb;21(2):103-115
pubmed: 31907406
Pharmaceutics. 2020 May 13;12(5):
pubmed: 32414195
Pharm Dev Technol. 2020 Jul;25(6):735-747
pubmed: 32141798
Crit Care Nurse. 2018 Oct;38(5):26-31
pubmed: 30275061
Clin Chim Acta. 2017 Mar;466:152-159
pubmed: 28088342
Mol Pharm. 2006 Jul-Aug;3(4):380-5
pubmed: 16889431
Int J Pharm. 2016 Nov 20;513(1-2):211-217
pubmed: 27615708
J Neural Transm Suppl. 2006;(71):1-15
pubmed: 17447410
Am J Med. 2019 Jul;132(7):802-807
pubmed: 30890425
Drug Deliv. 2016 Sep;23(7):2154-2162
pubmed: 25182182
J Mater Sci Mater Med. 2013 Sep;24(9):2101-15
pubmed: 23728521
P T. 2008 Apr;33(4):212-46
pubmed: 19750165
Curr Neuropharmacol. 2016;14(4):376-91
pubmed: 26714584
Clin Drug Investig. 2018 Apr;38(4):287-312
pubmed: 29327219
Front Mol Neurosci. 2019 Dec 05;12:299
pubmed: 31866823
J Drug Target. 2018 Feb;26(2):150-161
pubmed: 28682134
Drug Deliv. 2017 Nov;24(1):1112-1123
pubmed: 28782388
Expert Opin Drug Deliv. 2015;12(9):1459-73
pubmed: 25813361
Nanotechnology. 2012 Mar 9;23(9):095103
pubmed: 22327243
Rejuvenation Res. 2018 Oct;21(5):464-476
pubmed: 29717617
Biol Res. 2016 Jul 04;49(1):32
pubmed: 27378167
Int J Pharm. 2011 Aug 30;415(1-2):119-28
pubmed: 21645593
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
Curr Opin Neurol. 2018 Aug;31(4):439-447
pubmed: 29746402
Int J Nanomedicine. 2018 Jan 09;13:273-281
pubmed: 29391788
Autophagy. 2012 Sep;8(9):1389-91
pubmed: 22885599
Drug Dev Ind Pharm. 2014 Jul;40(7):869-78
pubmed: 23600649
J Pharm Sci. 2011 Feb;100(2):547-57
pubmed: 20740670
Lancet Neurol. 2005 Jun;4(6):366-70
pubmed: 15907741
Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S13-S21
pubmed: 27979722
Pharm Res. 2017 Jul;34(7):1459-1468
pubmed: 28405912
J Pharm Sci. 2008 Jan;97(1):123-43
pubmed: 17721949
J Adv Pharm Technol Res. 2014 Jul;5(3):115-21
pubmed: 25126532
Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):
pubmed: 28716886
Mov Disord. 2011 May;26(6):1072-82
pubmed: 21626552
Small. 2008 Jan;4(1):26-49
pubmed: 18165959
J Biomed Nanotechnol. 2014 Sep;10(9):2371-92
pubmed: 25992462
Artif Cells Nanomed Biotechnol. 2017 May;45(3):635-648
pubmed: 27068140
Biochem Biophys Res Commun. 2017 Jan 1;482(1):75-80
pubmed: 27810365
Lancet Neurol. 2016 Nov;15(12):1257-1272
pubmed: 27751556
Exp Mol Pathol. 2009 Jun;86(3):215-23
pubmed: 19186176
Ther Clin Risk Manag. 2018 Sep 18;14:1737-1745
pubmed: 30271159
Lancet Neurol. 2006 Jan;5(1):75-86
pubmed: 16361025
J Control Release. 2010 Apr 2;143(1):2-12
pubmed: 19925835
Front Neurol. 2020 Jan 21;10:1388
pubmed: 32038461
Nat Rev Dis Primers. 2017 Mar 23;3:17013
pubmed: 28332488
Molecules. 2017 Dec 25;23(1):
pubmed: 29295587
Int J Pharm. 2019 Nov 25;571:118697
pubmed: 31526839
Anal Chim Acta. 2016 Jan 1;902:107-114
pubmed: 26703259
Biomater Sci. 2019 Mar 26;7(4):1623-1631
pubmed: 30702723
CNS Drugs. 2005;19(11):973-81
pubmed: 16268667
Small. 2016 Jan 20;12(3):301-6
pubmed: 26619158
Curr Pharm Des. 2010 May;16(14):1644-53
pubmed: 20210751
Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):967-75
pubmed: 27224246
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
N Engl J Med. 2012 Oct 18;367(16):1529-38
pubmed: 23075179
CNS Drugs. 2019 Jul;33(7):707-718
pubmed: 31243728
Lancet. 2004 May 29;363(9423):1783-93
pubmed: 15172778
Int J Pharm. 2020 Apr 15;579:119148
pubmed: 32084576
Analyst. 2019 Jan 14;144(2):611-621
pubmed: 30457584
Drug Dev Ind Pharm. 2015;41(10):1674-81
pubmed: 25496439
Curr Neuropharmacol. 2018;16(9):1348-1357
pubmed: 29473513
Drug Dev Ind Pharm. 2018 Oct;44(10):1613-1621
pubmed: 29932793
Drug Dev Ind Pharm. 2003 Sep;29(8):821-32
pubmed: 14570303
Int J Pharm Investig. 2015 Apr-Jun;5(2):87-91
pubmed: 25838993
Nanoscale. 2015 Nov 28;7(44):18411-23
pubmed: 26508277
Biomaterials. 1988 Jan;9(1):111-5
pubmed: 3280037
J Nanobiotechnology. 2015 Mar 05;13:20
pubmed: 25890124
Expert Rev Neurother. 2011 Sep;11(9):1229-34
pubmed: 21864066
CNS Drugs. 2005;19(2):165-84
pubmed: 15697329
Ther Adv Neurol Disord. 2009 Nov;2(6):20-8
pubmed: 21180627
Lancet Neurol. 2018 Nov;17(11):939-953
pubmed: 30287051
Int J Cell Biol. 2013;2013:150952
pubmed: 24324497
Drug Dev Ind Pharm. 2013 Feb;39(2):321-30
pubmed: 22607101
Drug Deliv. 2013;20(1):47-56
pubmed: 23311653
Am Fam Physician. 2013 Feb 15;87(4):267-73
pubmed: 23418798
Ann Neurol. 2013 Sep;74(3):337-47
pubmed: 24038341
JAMA. 2020 Feb 11;323(6):548-560
pubmed: 32044947
Langmuir. 2015 Feb 3;31(4):1469-78
pubmed: 25561279
Arch Neurol. 1974 Aug;31(2):128-33
pubmed: 4834974
Cochrane Database Syst Rev. 2003;(2):CD003735
pubmed: 12804486
Neurotherapeutics. 2007 Jan;4(1):110-6
pubmed: 17199024
Int J Biol Macromol. 2018 Apr 1;109:27-35
pubmed: 29247729
Ageing Res Rev. 2018 Mar;42:72-85
pubmed: 29288112
Neurobiol Dis. 2020 Oct;144:105028
pubmed: 32736085
J Pharm Sci. 2020 Sep;109(9):2729-2734
pubmed: 32497595
Front Biosci (Schol Ed). 2014 Jan 01;6(1):65-74
pubmed: 24389262
Mov Disord. 2012 Nov;27(13):1606-11
pubmed: 23115047
J Neurosci Res. 2002 Feb 1;67(3):285-9
pubmed: 11813232
Drugs Aging. 2005;22(1):83-91; discussion 93-4
pubmed: 15663351
Lancet Neurol. 2016 Feb;15(2):154-165
pubmed: 26725544
Expert Rev Neurother. 2006 Sep;6(9):1275-82
pubmed: 17009915
Pharmaceutics. 2019 Jan 10;11(1):
pubmed: 30634665
AAPS PharmSciTech. 2009;10(1):69-76
pubmed: 19148761
Int J Nanomedicine. 2012;7:1599-611
pubmed: 22619515
ACS Chem Neurosci. 2014 Dec 17;5(12):1192-7
pubmed: 25270271
Expert Opin Drug Deliv. 2018 Apr;15(4):369-378
pubmed: 29338427
Int J Pharm. 2012 Jan 17;422(1-2):436-44
pubmed: 22057087
Nanotechnology. 2010 Oct 8;21(40):405101
pubmed: 20823498
FEBS J. 2013 Dec;280(23):5981-93
pubmed: 23663200
Med Clin North Am. 2019 Mar;103(2):337-350
pubmed: 30704685
Drugs. 2016 Sep;76(13):1293-1300
pubmed: 27498199
J Biomed Nanotechnol. 2014 Nov;10(11):3291-303
pubmed: 26000388
Nanoscale. 2011 Dec;3(12):5110-9
pubmed: 22037807
Nanomedicine (Lond). 2018 Sep;13(18):2341-2371
pubmed: 30088440
J Intern Med. 2013 May;273(5):426-8
pubmed: 23600397
Neurobiol Dis. 2017 Jul;103:101-112
pubmed: 28411117
Eur J Pharm Biopharm. 2011 Aug;78(3):422-31
pubmed: 21315820
CNS Drugs. 2010 Oct;24(10):829-41
pubmed: 20839895
J Nanobiotechnology. 2016 Jun 08;14(1):41
pubmed: 27278241
Expert Rev Neurother. 2011 Jul;11(7):925-35
pubmed: 21721909
Int J Pharm. 2015 Oct 15;494(1):49-65
pubmed: 26260231
J Biomater Sci Polym Ed. 2013;24(15):1740-56
pubmed: 23705812
Nanomedicine. 2019 Apr;17:236-245
pubmed: 30738234
Expert Rev Neurother. 2004 Jul;4(4):581-8
pubmed: 15853577
Sci Rep. 2017 Jan 09;7:40298
pubmed: 28067307
Brain Res. 2019 Mar 15;1707:141-153
pubmed: 30481502
Int J Pharm. 2009 Oct 1;380(1-2):33-9
pubmed: 19563870
Expert Rev Neurother. 2015 Jun;15(6):695-710
pubmed: 25955028
Nat Commun. 2016 Feb 03;7:10599
pubmed: 26837260
J Pharm Sci. 2016 Mar;105(3):1209-20
pubmed: 26886345
J Pharm Sci. 2009 Oct;98(10):3735-47
pubmed: 19156914
Ann Pharmacother. 2000 Sep;34(9):1056-65
pubmed: 10981253